Digital tools for clinical trials
To pave the way to faster, predictable, and more accessible clinical trials.
Downtown Crossing, Boston, MA
Some candidates hear
back within 2 weeks
-34% employee growth in 12 months
CEO of Otta
Clinical research remains a significant bottleneck on drug development. Much of this is due to the slow and unpredictable nature of patient enrolment. OneStudyTeam is tackling this problem with a platform that helps biopharma companies and research sites to enroll trials in three to four months instead of 18 months.
The company's tools are already being used by top-20 global biopharma companies such as Amgen, AstraZeneca, and Eli Lilly & Company, and across a total of over 5,000 research sites across 65 countries. In 2022, OneStudyTeam invested $220 million into improving diversity in clinical trials. This is a strong indicator of the company’s future-facing outlook and its impressive financial backing.
The business is scaling fast, reaching Unicorn status with its Series C round in 2021. If this trajectory continues, OneStudyTeam could become one of the leading names in the pharmaceutical and healthcare industries.
Last 2 fundraises
This company has top investors
Claim your profile to receive high quality applications from relevant candidates.Claim profile
For job seekers
Sign in or sign up to discover relevant roles at exciting companies.Sign in or sign up
OneStudyTeam currently has 0 jobs on Otta
We sync with OneStudyTeam's jobs every 8 hours, so check again soon